These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 30097887)

  • 41.
    Stone GG; Newell P; Bradford PA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
    Nichols WW; Bradford PA; Stone GG
    J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 45. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
    Merdjan H; Rangaraju M; Tarral A
    Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
    Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG; Bradford PA; Newell P; Wardman A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
    Alidjanov JF; Fritzenwanker M; Hoffman I; Wagenlehner FM
    Future Microbiol; 2017 Jun; 12():655-670. PubMed ID: 28338347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?
    Barber KE; Ortwine JK; Akins RL
    J Pharm Pharm Sci; 2016; 19(4):448-464. PubMed ID: 28057163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Avibactam Pharmacokinetic/Pharmacodynamic Targets.
    Nichols WW; Newell P; Critchley IA; Riccobene T; Das S
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.